Pharma: Page 16
-
Getty Images
Novo inks Ascendis deal to develop long-acting GLP-1, other metabolic drugs
Per terms, Novo could pay up to $285 million in upfront and milestone fees to Ascendis, which specializes in a kind of drug-enhancing technology.
By Jonathan Gardner • Nov. 4, 2024 -
Getty Images
Regeneron battles Wall Street uncertainty; Madrigal extends fast launch of MASH drug
Regeneron shares continued to decline on growing concerns about Eylea’s future. Elsewhere, new details emerged about Lundbeck’s Longboard buyout and PTC continued a quixotic quest.
By BioPharma Dive staff • Nov. 1, 2024 -
Explore the Trendline➔
National Institute on Aging. (2017). "Beta-Amyloid Plaques and Tau in the Brain" [Image]. Retrieved from Flickr.
TrendlineAlzheimer's disease
Many companies hope to follow in the footsteps of Biogen, Eisai and Eli Lilly by developing new therapies for the debilitating disease, which affects tens of millions of people and costs healthcare systems hundreds of billions of dollars each year.
By BioPharma Dive staff -
Getty Images
New Alzheimer's drugsRoche weighs whether speedy approval path is open for latest Alzheimer’s drug
In an investor presentation, executives hinted at the possibility of seeking an accelerated approval of trontinemab if it can significantly lower levels of amyloid in a Phase 3 trial.
By Jonathan Gardner • Oct. 31, 2024 -
Getty Images
Novo takes big step toward ending Ozempic, Wegovy shortages
All doses of the two drugs are now listed as available in the U.S., per an FDA database, although the company cautioned patients may still experience "variability" filling their prescriptions.
By Ned Pagliarulo • Updated Oct. 30, 2024 -
Warren Little via Getty Images
GSK vaccine sales sink on lower demand for RSV, shingles shots
The British pharma’s experience during the third quarter mirrored that of rival Pfizer, which also reported lower sales of its competing RSV shot.
By Delilah Alvarado • Oct. 30, 2024 -
Scott Olson via Getty Images
Lilly shares fall as obesity drug sales miss forecasts
Third quarter Mounjaro and Zepbound sales, while up substantially versus the same period last year, grew little compared to the second quarter as wholesalers bought less supply.
By Ned Pagliarulo • Updated Oct. 30, 2024 -
Jeenah Moon via Getty Images
Pfizer sales of RSV vaccine ebb, but company gains market share
New guidelines and the timing of COVID vaccinations impacted uptake of Abrysvo this year, according to a company executive.
By Delilah Alvarado • Oct. 29, 2024 -
Leon Neal via Getty Images
GSK to pay $300M to license drug it sees as potential lupus treatment
The deal with China’s Chimagen Biosciences is the latest example of pharma interest in exploring the potential of “T cell engagers” in autoimmune disease.
By Ned Pagliarulo • Oct. 29, 2024 -
Getty Images
Biogen refreshes its C-suite; Novartis writes down MorphoSys assets
Daniel Quirk, an immunology and neuroscience executive at Bristol Myers Squibb, will be Biogen’s next chief medical officer. Meanwhile, Robin Kramer will replace retiring CFO Michael McDonnell.
By BioPharma Dive staff • Oct. 29, 2024 -
Permission granted by Pfizer
Pfizer answers Starboard challenge with beat-and-raise quarter
Company CEO Albert Bourla said Pfizer would consider “any good ideas” that create value, but argued it has already made important changes to improve the business.
By Ned Pagliarulo • Updated Oct. 29, 2024 -
Permission granted by FedEx
Sponsored by FedEx OfficeHow pharmaceutical companies can leverage print to remain agile and competitive
Learn why print remains a preferred channel for healthcare communications, and how printed materials can help build relationships with patients, develop brand loyalty and maintain brand consistency.
Oct. 28, 2024 -
Courtesy of Sanofi
Sanofi earnings boosted by Beyfortus, earlier vaccine sales
Sanofi and partner AstraZeneca recently increased production capacity for their RSV antibody shot, sales of which jumped during the third quarter.
By Delilah Alvarado • Oct. 25, 2024 -
Getty Images
GSK invests $800M in manufacturing; Amgen sets small discount for Eylea biosimilar
The British pharma is making what it calls its largest U.S. manufacturing investment. Elsewhere, Roche and Dyno expanded their alliance to create better viral vectors for use in gene therapy.
By BioPharma Dive staff • Oct. 25, 2024 -
Kevin C. Cox via Getty Images
Merck, Pfizer lifted as CDC backs broader use of pneumococcal vaccines
An agency panel recommended lowering the age for routine vaccination from 65 to 50, boosting the revenue outlook for multiple shots on the market and in development.
By Delilah Alvarado • Oct. 24, 2024 -
Buda Mendes via Getty Images
Dengue is spreading and Sanofi is pulling the US market’s only vaccine. What’s next?
As Sanofi prepares to halt U.S. marketing of its dengue vaccine in 2026, locally acquired infections in the country are raising alarms.
By Alexandra Pecci • Oct. 24, 2024 -
Permission granted by BIO
Q&A // Emerging biotechJ&J’s Asish Xavier on biotech’s rebound in a volatile era
Xavier, who leads biotech venture investing for the big drugmaker, expects an uptick in IPOs as well as renewed interest in the newer crop of gene and cell therapy companies.
By Gwendolyn Wu • Oct. 24, 2024 -
Getty Images
Merck acquires cancer drug startup; Elevidys ex-US sales rise
Yale spinout Modifi agreed to sell to Merck for $30 million upfront. Elsewhere, Sangamo plotted a much faster path to market for its Fabry gene therapy.
By BioPharma Dive staff • Oct. 23, 2024 -
Getty Images
Starboard makes case for change at Pfizer, citing research, M&A missteps
The activist investor claims Pfizer failed to capitalize on the windfall earned from its COVID-19 vaccine and, in the process, destroyed tens of billions of dollars in market value.
By Ned Pagliarulo • Oct. 22, 2024 -
Courtesy of Sanofi
Sanofi moves ahead with CD&R deal for stake in consumer business
Under the proposed deal, the PE firm would take a controlling 50% stake in Sanofi’s Opella unit, with state-owned Bpifrance taking a minority 2% position.
By Delilah Alvarado • Oct. 21, 2024 -
Courtesy of Novo Nordisk
Oral version of Novo diabetes drug protects heart health in large study
The medicine, which Novo sells as Rybelsus, cut the risk of cardiovascular complications by 14% when added to standard therapies in people with diabetes and heart disease.
By Jonathan Gardner • Oct. 21, 2024 -
Getty Images
Sponsored by SyngeneHarnessing the power of upstream platform integration to accelerate biopharma innovation
Learn how Syngene’s integrated strategy can enhance your mAb production capabilities.
Oct. 21, 2024 -
Getty Images
PTC rebuffed again by EMA; Novartis licenses China-based biotech’s cancer drug
European regulators have for the fourth time issued a negative opinion on PTC's Translarna. Elsewhere, Amylyx read out data and Leqembi hit a roadblock in Australia.
By BioPharma Dive staff • Oct. 18, 2024 -
Courtesy of AbbVie
After rejections, AbbVie secures approval for Parkinson’s drug
Vyalev’s clearance is the second victory for AbbVie in Parkinson’s this year, following an April readout for a drug acquired through its Cerevel buyout.
By Jacob Bell • Oct. 17, 2024 -
Getty Images
Sanofi, expanding in radiopharma, strikes a joint venture deal
The French drugmaker will invest 300 million euros into a new entity that will develop lead isotope-based therapies for cancer under the Orano Med brand.
By Ned Pagliarulo • Oct. 17, 2024 -
Courtesy of GSK
GSK claims Moderna infringed mRNA vaccine patents
The pharma’s lawsuit focuses on scientific work that helped clear the path for creating mRNA vaccines to fight the COVID-19 pandemic.
By Kristin Jensen • Oct. 16, 2024
Previous
